ALT Altimmune Inc
- Stocks
- Healthcare
- NASDAQ: ALT
Price (delayed)
$3.75
Market cap
$330.96M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.18
Enterprise value
$162.15M
Relative Growth:
Rel. Growth:
15
Relative Strength:
Rel. Strength:
14
Relative Valuation:
Rel. Valuation:
1
Relative Profitability:
Rel. Profitability:
32
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™),
Highlights
ALT's quick ratio has soared by 82% YoY and by 30% QoQ
Altimmune's EPS has increased by 28% YoY and by 6% QoQ
The gross profit has plunged by 96% YoY
ALT's revenue has dropped by 96% year-on-year
Key stats
What are the main financial stats of ALT
Market
Valuations
Earnings
Shares outstanding
88.26M
Market cap
$330.96M
Enterprise value
$162.15M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.88
Price to sales (P/S)
20,369.39
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10,809.98
Revenue
$15,000
Gross profit
$15,000
Operating income
-$94.38M
Net income
-$87.75M
EBIT
-$88.16M
EBITDA
-$88.03M
Free cash flow
-$81.58M
Per share
Balance sheet
Liquidity
EPS
-$1.18
EPS diluted
-$1.18
Free cash flow per share
-$1
Book value per share
$1.99
Revenue per share
$0
TBVPS
$2.34
Total assets
$190.35M
Total liabilities
$28.98M
Debt
$14.33M
Equity
$161.37M
Working capital
$179.2M
Debt to equity
0.09
Current ratio
20.44
Quick ratio
19.9
Net debt/EBITDA
1.92
Margins
Efficiency
Dividend
EBITDA margin
-586,840%
Gross margin
100%
Net margin
-584,973.3%
Operating margin
-629,166.7%
Return on assets
-55.3%
Return on equity
-62.6%
Return on invested capital
-113.7%
Return on capital employed
-48.7%
Return on sales
-587,700%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALT stock price
How has the Altimmune stock price performed over time
Intraday
-0.27%
1 week
-6.25%
1 month
-4.09%
1 year
-46.66%
YTD
-47.99%
QTD
-0.53%
Financial performance
How have Altimmune's revenue and profit performed over time
Revenue
$15,000
Gross profit
$15,000
Operating income
-$94.38M
Net income
-$87.75M
Gross margin
100%
Net margin
-584,973.3%
The gross profit has plunged by 96% YoY
ALT's revenue has dropped by 96% year-on-year
Altimmune's operating income has increased by 14% YoY and by 3.9% from the previous quarter
Altimmune's net income has increased by 13% YoY and by 2.8% QoQ
Price vs fundamentals
How does ALT's price correlate with its fundamentals
Growth
What is Altimmune's growth rate over time
Valuation
What is Altimmune stock price valuation
P/E
N/A
P/B
1.88
P/S
20,369.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10,809.98
Altimmune's EPS has increased by 28% YoY and by 6% QoQ
The P/B is 37% lower than the last 4 quarters average of 3.0 and 22% lower than the 5-year quarterly average of 2.4
The equity has increased by 14% since the previous quarter and by 6% year-on-year
ALT's revenue has dropped by 96% year-on-year
Efficiency
How efficient is Altimmune business performance
The company's return on invested capital fell by 25% QoQ but it rose by 11% YoY
ALT's ROA is up by 5% QoQ
The return on equity rose by 4.3% since the previous quarter but it has declined by 3.5% year-on-year
Altimmune's return on sales has increased by 3% QoQ
Dividends
What is ALT's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history
Special dividends are included in TTM DPS and yield
Financial health
How did Altimmune financials performed over time
The total liabilities has soared by 92% since the previous quarter and by 39% year-on-year
ALT's quick ratio has soared by 82% YoY and by 30% QoQ
The debt is 91% smaller than the equity
The equity has increased by 14% since the previous quarter and by 6% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.